EyePoint (EYPT) expects its cash, cash equivalents, and marketable securities as of September 30, 2025, along with the net proceeds from the October equity financing, will enable the Company to fund operations into the fourth quarter of 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target raised to $33 from $28 at Mizuho
- EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint Pharmaceuticals Raises $141M in Public Offering
- EyePoint reports inducement grants under NASDAQ listing rule